Intern, Asset Acquisition

Job Description

Job Description

Description : About GondolaBio

GondolaBio is a clinical-stage biopharmaceutical company focused on developing next-generation therapeutics for genetic diseases. Originally launched as BridgeBioX, a subsidiary of BridgeBio, GondolaBio secured $300M in private financing from external investors in 2024 and became an independent company within the BridgeBio ecosystem. The company aims to leverage cutting-edge biological research to create breakthrough medicines addressing high unmet needs across multiple therapeutic areas, including neurology, pulmonology, cardiology, nephrology, and endocrinology. Located on the Stanford Life Sciences campus, GondolaBio fosters a unique hybrid environment where top scientists from around the world collaborate with senior leadership and advisors, blending industry expertise with academic innovation.

About BridgeBio

BridgeBio is a biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases and cancers with clear genetic drivers. We bridge the gap between remarkable advancements in genetic science in academic institutions and the delivery of meaningful medicines to patients. Founded in 2015, the company has built a portfolio of 20 drug development programs ranging from preclinical to late-stage development in multiple therapeutic areas including genetic dermatology, precision oncology, cardiology, endocrinology, neurology, pulmonology, and renal disease, with two approved drugs.

Our focus on scientific excellence and rapid execution aim to translate today’s discoveries into tomorrow’s medicines. We have U.S. offices in San Francisco, Palo Alto, and Raleigh, with small satellites in other parts of the country. We also have international offices in Montreal, Canada, and Zurich, Switzerland, and are expanding across Europe.

To learn more about our story and company culture, visit us at https : / / bridgebio.com

Who You Are

GondolaBio’s Asset Acquisition team is seeking an Intern to help us define our new programs. We are looking for ambitious scientists who’d like to contribute at the intersection of science and business. This team member will stay abreast of the latest publications and conferences and communicate key findings to the discovery team and scientific leadership. This is a great opportunity to utilize your scientific background and training, while gaining experience in key aspects of drug development from genetic rationale and pre-clinical evidence all the way to the development plan and clinical trial design.

The Asset Acquisition team is responsible for finding, evaluating, and determining which therapeutic ideas GondolaBio will pursue, with an emphasis on the evaluation of the scientific rationale behind therapeutic strategies. The team works closely with GondolaBio’s Investment Committee, which is composed of veteran drug developers and renowned academic scientists. Across the BridgeBio ecosystem, we have spearheaded partnerships with academic and industry groups to create, fund, and operate >

30 new drug development programs.

Requirements : Responsibilities

• Drive?innovation sourcing efforts by screening?literature and conferences?for meaningful advances in genetic medicine
• Communicate?latest findings?to senior audience that synthesizes key new information and implications?
• Join outreach efforts to dive deeper into research of interest to the team, including discussions with leading academics, patient advocacy groups, biotechs, and entrepreneurs
• Learn about how a biotechnology company evaluates, selects, and launches new drug development efforts to serve patients living with genetic diseases
• Have the opportunity to advocate for new programs that that fit our goal of targeting the genetic source of a disease by building a scientific and business case for each potential investment

No matter your role at BridgeBio, successful team members are :

Education, Experience & Skills Requirements

What We Offer